Corporate Advisory and Governance, Equity Capital Markets, Mergers and Acquisitions, White Collar Crime, ESG, Food and Agribusiness, International, Life Sciences, Resources and Renewables, Start-ups and Emerging Businesses, Technology, Media, and Telecommunications
From startups to initial public offerings (IPOs), through to expanding market capitalisation via secondary fundraisings, Reece has strong working relationships with issuers, shareholders, underwriters and regulators (ASX and ASIC) allowing a deep understanding of current market practice and trends.
With deep knowledge of the Corporations Act and ASX Listing Rules, he advises clients across governance, due diligence, stakeholder management, employee share and option plans, and general commercial issues, ensuring his clients receive sound advice across complex legislative environments. As a trusted advisor to boards and senior management, Reece provides practical and tailored regulatory compliance advice including modern slavery, anti-bribery and corruption, sanctions, whistleblower obligations and industry specific codes and regulations.
Reece has advised clients across the life sciences, technology, telecommunications, travel, food and agribusiness, built environmental and renewables industries and serves as Deputy Chair on St Aidan’s School Council.
Leading McCullough Robertson’s Life Sciences group, Reece has advised health and life sciences companies, universities and research institutes on regulatory and transactional matters and has supported companies in securing venture capital and private equity investment. As an active member of Life Sciences Queensland and an active member of AusBiotech, Reece is a passionate supporter of the industry.
Decoding medical device classification for femtech software
Former Irexchange executives in the sights for alleged misleading prospectus
The FTX collapse: The governance red flags top-tier investors ignored
Numerous including LGI (Landfill Gas Industries), Chimeric Therapeutics, Radiopharm Theranostics, Naked Brand Group, MSL Solutions, Oventus Medical, Wagners, Over the Wire, Other Levels, Anatara Lifesciences, Corporate Travel Management, Seymour Whyte, Ausenco, Genera Biosystems, Invion, Provet and GBST.
Numerous including Ausenco, Corporate Travel Management, Carbon Energy, Viralytics, Factor Therapeutics, Other Levels, Invion, Imugene, Lindsay Australia and Prescient Therapeutics.
Advised Radiopharm Theranostics (ASX: RAD) in raising more than $150 million, including its $70 million placement, in parallel with supporting its NASDAQ listing, its $12.5 million capital raise with US institutional investor, Lind Partners, and its acquisition of Pharma15 Corporation.
Advising Over the Wire Limited on its $390.4 million sale to Aussie Broadband, via a scheme of arrangement, having previously advised on Over the Wire’s acquisitions of Faktortel, Sanity, Spiderbox, Telarus, Comlinx, Access Digital, Cloud Connect, Zintel Communications (NZ), and Digital Sense Hosting.
Advised Imugene Limited (ASX: IMU) in raising more than $270 million, including $46 million via convertible notes and up to a further $26 million in warrants, $53.2 million via a placement and share purchase plan, $80 million institutional placement with $66 million in attached options, and a $90 million placement.
Advising a range of specialised funds and investee companies with a focus on technology and creative industries.
Successfully assisting E3 Advisory in its sale to London Stock Exchange listed Ricardo Group plc (RCDO), delivering a $101.4 million sale of an 85% interest, allowing the global consulting firm to take a leading position in Australia’s market.
Advising on the $502 million acquisition of Viralytics Limited by Merck by scheme of arrangement and subsequent secondary capital raisings totalling over $180 million.
